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Genetic pathways to glioblastoma: a population-based study
Abstract
We conducted a population-based study on glioblastomas in the Canton of Zurich, Switzerland
(population, 1.16 million) to determine the frequency of major genetic alterations and their effect on
patient survival. Between 1980 and 1994, 715 glioblastomas were diagnosed. The incidence rate per
100,000 population/year, adjusted to the World Standard Population, was 3.32 in males and 2.24 in
females. Observed survival rates were 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years. For all
of the age groups, younger patients survived significantly longer, ranging from a median of 8.8 months
(<50 years) to 1.6 months (>80 years). Loss of heterozygosity (LOH) 10q was the most frequent genetic
alteration (69%), followed by EGFR amplification (34%), TP53 mutations (31%), p16(INK4a) deletion
(31%), and PTEN mutations (24%). LOH 10q occurred in association with any of the other genetic
alterations and was predictive of shorter survival. Primary (de novo) glioblastomas prevailed (95%),
whereas secondary glioblastomas that progressed from low-grade or anaplastic gliomas were rare (5%).
Secondary glioblastomas were characterized by frequent LOH 10q (63%) and TP53 mutations (65%).
Of the TP53 mutations in secondary glioblastomas, 57% were in hotspot codons 248 and 273, whereas
in primary glioblastomas, mutations were more equally distributed. G:C-->A:T mutations at CpG sites
were more frequent in secondary than primary glioblastomas (56% versus 30%; P = 0.0208). This
suggests that the acquisition of TP53 mutations in these glioblastoma subtypes occurs through different
mechanisms.
[CANCER RESEARCH 64, 6892–6899, October 1, 2004]
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ABSTRACT
We conducted a population-based study on glioblastomas in the Canton
of Zurich, Switzerland (population, 1.16 million) to determine the fre-
quency of major genetic alterations and their effect on patient survival.
Between 1980 and 1994, 715 glioblastomas were diagnosed. The incidence
rate per 100,000 population/year, adjusted to the World Standard Popu-
lation, was 3.32 in males and 2.24 in females. Observed survival rates were
42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years. For all of the
age groups, younger patients survived significantly longer, ranging from a
median of 8.8 months (<50 years) to 1.6 months (>80 years). Loss of
heterozygosity (LOH) 10q was the most frequent genetic alteration (69%),
followed by EGFR amplification (34%), TP53 mutations (31%), p16INK4a
deletion (31%), and PTEN mutations (24%). LOH 10q occurred in asso-
ciation with any of the other genetic alterations and was predictive of
shorter survival. Primary (de novo) glioblastomas prevailed (95%),
whereas secondary glioblastomas that progressed from low-grade or ana-
plastic gliomas were rare (5%). Secondary glioblastomas were character-
ized by frequent LOH 10q (63%) and TP53 mutations (65%). Of the TP53
mutations in secondary glioblastomas, 57% were in hotspot codons 248
and 273, whereas in primary glioblastomas, mutations were more equally
distributed. G:C3A:T mutations at CpG sites were more frequent in
secondary than primary glioblastomas (56% versus 30%; P  0.0208).
This suggests that the acquisition of TP53 mutations in these glioblastoma
subtypes occurs through different mechanisms.
INTRODUCTION
Glioblastomas are the most frequent and malignant human brain
tumors, and despite advances in surgical and clinical neuro-oncology,
their prognosis remains poor. In a meta-analysis of 12 randomized
clinical trials, the overall survival rate of high-grade gliomas (e.g.,
glioblastomas and anaplastic astrocytomas) was 40% at 1 year and
only slightly higher (46%) after combined radiotherapy and chemo-
therapy (1). Even these depressingly low survival rates may be over-
optimistic because trial protocols contain admission criteria that often
exclude patients with a particularly unfavorable clinical course.
Therefore, this study assessed survival on a population-based level.
From a clinical and biological point of view, a distinction between
primary and secondary glioblastoma is important. Primary (de novo)
glioblastomas manifest rapidly, without evidence of less malignant
precursor lesions, after a short clinical history. Secondary glioblasto-
mas develop more slowly by progression from low-grade [World
Health Organization (WHO) grade II] or anaplastic astrocytoma
(WHO grade III; ref. 2). These glioblastoma subtypes affect patients
at different ages and through different genetic pathways (2, 3). How-
ever, no data are available on the relative frequency of these glioblas-
toma subtypes at a population level.
Oncogenes (EGFR, PDGF and its receptors) and tumor suppressor
genes (p16INK4a, p14ARF, PTEN, RB1, and TP53) are involved in the
evolution of glioblastomas. Frequent loss of heterozygosity (LOH) at
1p, 10p, 10q, 19q, and 22q suggests the participation of additional
tumor suppressor genes (2, 4–6). Whereas older age was shown to be
predictive of poorer prognosis in several studies, the definition of
genetic alterations predictive of response to therapy has been incon-
clusive, at least in part because of the usually small number of cases
investigated (2, 7).
The present study is the first to examine key genetic alterations in
glioblastomas and their impact on survival rates in a large population-
based series of cases. It is based on 715 inhabitants of the Canton of
Zurich, Switzerland who developed a glioblastoma during the period
1980 to 1994. We assessed the incidence of glioblastoma subtypes,
survival rates, and key genetic alterations in this defined population.
MATERIALS AND METHODS
Patient Population. This study included 715 newly diagnosed cases of
glioblastoma (International Classification of Diseases for Oncology 94403,
94413, and 94423; ref. 2) that occurred in the resident population of the Canton
of Zurich, Switzerland (1.16 million) during the 15-year period 1980 through
1994 (8). The incidence date was fixed as the date of the pathology report for
patients who underwent surgery or the date of clinical diagnosis otherwise
(including autopsied cases). Clinical diagnoses were based on CT or MRI.
Survival time was computed as the time between the incidence date and the
date of death, date of last contact if lost from follow-up evaluation, or
December 31, 1999. Follow-up evaluation was complete for 99% of the cases
with the mean follow-up time of 7.2  7.6 months. Death certificates were
collected at the Cantonal Cancer Registry. The mean age of patients was
61.3  14.0 years. The age distribution of patients was as follows: 39 years,
6.9%; 40 through 49 years, 12.5%; 50 through 59 years, 21.1%; 60 through 69
years, 29.9%; 70 through 79 years, 22.1%; and 80 years, 7.6%.
Histology Review. The 715 glioblastomas included 8 giant-cell glioblas-
tomas and 5 gliosarcomas. The majority of cases (571 cases, 80%) were
histologically confirmed following surgical intervention (385 cases, 54%) or at
autopsy (186 cases, 26%). The remaining 144 cases (20%) were clinically
diagnosed only by CT or MRI, typically based on the presence of an irregularly
shaped lesion of contrast enhancement with a central area of necrosis and
perifocal edema (2). The original histologic specimens of 549 of 571 (96%)
histologically diagnosed cases were reevaluated by two neuropathologists
(P-L.D.P., P.K.) according to the new WHO classification of tumors of the
nervous system (2).
Glioblastoma Subtypes. The following criteria were used to distinguish
between glioblastoma subtypes: Tumors were considered primary (de novo)
when the glioblastoma diagnosis was made at the first biopsy, without clinical
or histopathologic evidence of a less malignant precursor lesion. The diagnosis
of secondary glioblastoma was made only in cases with histopathologic evi-
dence of preceding low-grade or anaplastic glioma.
Treatment. Approximately half of the patients (384 of 715; 54%) with
glioblastomas underwent partial or complete surgical resection, usually at the
Department of Neurosurgery, University Hospital, Zurich. The mean age of
patients who underwent partial or complete surgical resection was significantly
younger (56.1  12.7 years) than those who did not undergo surgery
(67.5  12.8 years; P  0.0001). Survival rates of patients who underwent
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partial or complete surgical resection were significantly longer (median,
7.9  0.5 months) than those who did not undergo surgery (2.5  0.1 months;
P 0.001). Information on radiotherapy was available for 494 cases (69%); of
these, 307 (62%) received radiotherapy, usually with 2-Gy fractions and a total
dose of 60 Gy. The mean age of patients who received radiotherapy was
54.6  11.4 years, significantly younger than those who did not receive
radiotherapy (68.4  12.7 years; P  0.0001). The survival rate of patients
who received radiotherapy was significantly longer (median, 10 1.2 months)
than those who did not receive radiotherapy (2.0  0.3 months; P  0.001).
TP53 Mutations. DNA was extracted from paraffin sections as reported
previously (9). Prescreening for mutations in exons 4 through 8 of the TP53
gene by PCR–single-strand conformational polymorphism analysis was carried
out as described previously (9). Primers for exon 4 were 5-ACTGCTCTTT-
TCACCCATCTAC-3 (sense) and 5-TCATGGAAGCCAGCCCCTCAG-3
(antisense). Samples that showed mobility shifts in single-strand conforma-
tional polymorphism analysis were further analyzed by direct DNA sequencing
on an automated sequencing system (ABI PRISM 3100 Genetic Analyzer;
Applied Biosystems, Foster City, CA) using an ABI PRISM BigDye Termi-
nator version 1.1 Cycle Sequencing Ready Reaction Kit (Applied Biosystems).
EGFR Amplification. To detect EGFR amplification, differential PCR
was performed as described previously (10) using the cystic fibrosis (CF)
sequence as a reference. After PCR (26 to 30 cycles), PCR products were
separated on 8% acrylamide gels using a Bio-Rad electrophoresis system
(Bio-Rad, Hercules, CA). Gels were stained with ethidium bromide and
digitalized using the Digital Science 1D analysis system (Kodak Digital
Science, New Haven, CT). Quantitative analysis of the signal intensity was
performed with the PhosphorImager 445 SI and the ImageQuant software
(Molecular Dynamics, Urbana, IL). The mean EGFR to CF ratio of normal
control DNA (peripheral blood of healthy adult donors) was 1.11  0.05
(mean  SD). The value of 2.36 (2 mean  3 SD) was regarded as the
threshold for evidence of EGFR amplification (10).
Differential PCR for p16INK4a Homozygous Deletion. To assess p16INK4a
homozygous deletion, differential PCR was carried out using a primer set
located in exon 1 of the p16INK4a gene and a -actin sequence as a reference
as reported previously (11). Briefly, DNA was amplified with 30 cycles of
PCR, and the PCR products were separated on 7% acrylamide gels. Gels were
photographed using a DC120 Zoom Digital Camera (Kodak, Rochester, NY),
and densitometry of the PCR fragments was performed as described previ-
ously. Samples in which the p16INK4a to -actin ratio was 0.20 were
considered as having homozygous deletion (11).
PTEN Mutations. Prescreening for mutations in exons 1 through 9 of the
PTEN gene by PCR–single-strand conformational polymorphism analysis was
carried out as described previously (10). Samples that showed mobility shifts
in single-strand conformational polymorphism analysis were further analyzed
by direct DNA sequencing on an automated sequencing system as described
previously (10).
Quantitative Microsatellite Analyses for LOH on Chromosome 10q.
Quantitative microsatellite analysis was carried out using two microsatellite
markers on chromosome 10q (12). The microsatellite markers are located
within the commonly deleted regions of 10q23 (D10S536) and 10q25
(D10S1683). PCR reactions were performed in a total volume of 12.5 L with
2 TaqMan Universal PCR Master Mix, 0.4 mol/L of each primer, 60
nmol/L probe [21-bp oligomer complementary to the microsatellite CA repeat:
5,6-carboxyfluorescein (FAM)-TGT GTG TGT GTG TGT GTG TGT-3
6-carboxy-tetramethylrhodamine], and 10 ng DNA, with cycling parameters
as reported previously (12). Primers, probe, and the TaqMan master mix were
purchased from Proligo Primers and Probes (Paris, France), and PCR was
carried out for each individual DNA in triplicate on a 96-well optical plate with
an ABI 7900HT instrument (Applied Biosystems). The amplification of a
reference pool of six reference loci served to normalize for differences in the
amount of total input DNA as described previously (12). To calculate the
average Ct [CT (normal)], DNA was isolated from 10 formalin-fixed,
paraffin-embedded normal tissues. The Ct, Ct [Ct (microsatellite)  Ct
(reference pool)], Ct [Ct (tumor)  Ct (normal)] values, the relative copy
number (2–Ct), and the tolerance interval (TI) with a confidence of 95%
determined from the pooled SD of normal DNA for both microsatellite loci
were calculated as reported previously (12). On the basis of this TI, copy
numbers1.42 were considered to represent losses, whereas those2.81 were
considered to be gains.
Statistical Analyses. The mean annual incidence rates per 100,000 popu-
lation by sex were age-adjusted to the World Standard Population, the Euro-
pean Population, and to the United States standard of 2000 (13) and were
calculated using 5-year age groups. Ninety-five percent confidence intervals
(CIs) were calculated after the logarithm transformation. Student’s t test was
carried out to compare the mean age of patient groups. The log-rank test was
carried out to assess univariate comparisons in survival rates. Multivariate
Cox’s regression was carried out to identify predictive factors of survival of
glioblastoma patients. Logistic regression analysis was carried out to assess
associations between different genetic alterations.
RESULTS
Incidence Rates. The incidence rates of glioblastomas for the
years 1980 through 1994, age-adjusted to the World Standard Popu-
lation, were 3.32 (CI, 2.69–4.09) for male cases and 2.24 (CI,
1.56–3.22) for female cases. The rates were higher when adjusted
using the United States standard population, 4.63 (CI, 3.83–5.59) in
male cases and 2.88 (CI, 2.18–3.79) in female cases.
Survival of Glioblastoma Patients. The median survival time of
all of the glioblastoma patients after glioblastoma diagnosis was 4.9
months. Observed survival rates of glioblastoma patients were 42.4%
at 6 months, 17.7% at 1 year, 3.3% at 2 years, and 1.2% at 3 years.
Age and Sex. Univariate and multivariate analyses showed that old
age is a significant predictive factor for poor survival of glioblastoma
patients (Fig. 1). Younger patients (50 years) showed significantly
longer survival (median, 8.8 months) than older patients (50 years;
median, 4.1 months; P  0.001). Among patients 50 years, age was
predictive of observed survival rates (Fig. 1). The male to female ratio
of all of the glioblastoma patients was 1.28.
Glioblastoma Subtypes. In 38 glioblastomas (5.3% of all of the
glioblastomas in this population), there was clinical and histopatho-
logic evidence of progression from a less malignant precursor lesion,
and these were diagnosed as secondary glioblastomas. The remaining
677 patients with glioblastoma (94.7%) showed neither clinical nor
histopathologic evidence of evolution from a less malignant lesion
and were classified as primary glioblastoma.
Primary glioblastomas developed in older patients (mean, 62
years), and secondary glioblastomas developed in middle-aged indi-
viduals (Figs. 2A and 3). Primary glioblastomas developed more
frequently in male cases, and secondary glioblastomas were more
frequently found in female cases (Fig. 3). Log-rank test showed that
patients with primary glioblastomas had significantly shorter survival
than those with secondary glioblastoma (Fig. 4), but age-adjusted
multivariate analysis showed no significant difference.
Frequency of Genetic Alterations. The most frequent genetic
alteration in glioblastomas was LOH 10q (69%), followed by EGFR
amplification (34%), TP53 mutations (31%), p16INK4a homozygous
deletion (31%), and PTEN mutations (24%). Similar frequencies of
genetic alterations were observed in primary glioblastomas (Fig. 3). In
secondary glioblastomas, TP53 mutations and LOH 10q were frequent
(65% and 63%), whereas the other alterations were infrequent (4 to
19%; Fig. 3). Univariate analysis showed that absence of TP53
mutations and presence of LOH 10q were predictive of shorter sur-
vival of patients (Fig. 4). However, after age-adjustment (multivariate
Cox’s regression analysis), only the presence of LOH 10q was asso-
ciated with shorter patient survival (P  0.067). Patients with glio-
blastoma carrying a TP53 codon 175 mutation showed shorter sur-
vival (median, 4.5 months) than those carrying the other mutation (7.8
months), but the difference was not statistically significant (P 0.17).
Copresence of Genetic Alterations. For 240 glioblastomas, data
were available on TP53 mutations, EGFR amplification, p16INK4a
homozygous deletion, PTEN mutations, and LOH 10q. The most
frequent combinations were LOH 10q and EGFR amplification
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(25.8%), LOH 10q and TP53 mutations (23.7%), and LOH 10q and
p16INK4a homozygous deletion (23.3%), followed by p16INK4a ho-
mozygous deletion and EGFR amplification (17.0%) and LOH 10q
and PTEN mutations (16.2%), whereas other combinations of genetic
alterations were infrequent (Fig. 5A).
Univariate and multivariate analyses showed that EGFR amplifica-
tion and p16INK4a deletion tend to occur simultaneously (Fig. 5A and
B). In contrast, TP53 mutations, p16INK4a deletion, EGFR amplifica-
tion, and PTEN mutations showed inverse associations with each
other (Fig. 5A and B).
Type and Distribution of TP53 Mutations and Polymorphisms.
One hundred seventy TP53 mutations were observed in 126 of 402
glioblastomas analyzed (31%). Double mutations were found in 26
cases; three mutations were found in 7 cases; and four mutations were
found in 1 case. Of 170 mutations, 145 (85.3%) were missense
mutations leading to amino acid change, 5 (2.9%) were nonsense
mutations, 10 (5.9%) were deletions leading to stop codons, 1 (0.6%)
was insertion leading to a stop codon, 5 (2.9%) were in-frame dele-
tions, 1 (0.6%) was in-frame insertion, and 3 (1.8%) were splicing
mutations. Fifty-three percent of deletions and insertions were located
in codons 150 through 167.
In secondary glioblastomas, 57% of point mutations were in codons
248 and 273, whereas in primary glioblastomas, point mutations were
Fig. 1. Kaplan-Meier curves showing that younger age of patients
with glioblastoma is predictive for longer survival (log-rank test: 50
years versus50 years, P 0.001; 50 to 59 years versus 60 to 69 years,
P  0.001; 60 to 69 years versus 70 to 79 years, P  0.001; 70 to 79
years versus 80 years; P  0.0261). On the basis of these data,
formulae were established to calculate the median and mean survival
time from the date of glioblastoma diagnosis (right).
Fig. 2. A, cumulative age distribution of patients with primary and secondary glio-
blastomas. Secondary glioblastomas develop in younger patients than primary glioblas-
tomas. B, cumulative age distribution of patients with glioblastomas with TP53 mutations
and those with EGFR amplification. TP53 mutations are present in glioblastomas in all of
the age groups of patients, whereas no glioblastomas in patients 35 years show EGFR
amplification.
Fig. 3. Timing and frequency of genetic alterations during astrocytoma progression.
The data of TP53 mutations in low-grade astrocytomas (21) and anaplastic astrocytomas
(unpublished data) are from the same population but are not necessarily from the same
patients. Note that LOH 10q is frequent in primary and secondary glioblastomas, and
TP53 mutations are early and frequent genetic alterations in the pathway leading to
secondary glioblastomas. , Genetic alterations that are significantly different in fre-
quency between primary and secondary glioblastomas.
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more equally distributed through exons (17% in codons 248 and 273;
P  0.001; Fig. 6). G:C3A:T mutations at CpG sites were signifi-
cantly more frequent in secondary glioblastomas (56%) than in pri-
mary glioblastomas (30%).
The status of codon 72 polymorphism in glioblastomas was Arg/
Arg, 58.4%; Arg/Pro, 33.8%; and Pro/Pro, 7.8%, which was similar to
the allelic frequencies reported for healthy Caucasians (14).
Type and Distribution of PTEN Mutations. Seventy-eight PTEN
mutations were observed in 77 glioblastomas (23.5%). Of these,
33.3% were missense mutations leading to amino acid change and
preferentially located in exons 1 to 6 (i.e., in the region homologous
to tensin, auxilin, and dual-specificity phosphatases; Fig. 6). Nonsense
mutations (12.8%) and deletions or insertions leading to stop codons
(32.1%) were located more equally distributed throughout the exons
Fig. 4. Survival of glioblastoma patients. Kaplan-Meier curves show that survival of patients with secondary glioblastoma is significantly longer than that of those with primary
glioblastoma (log-rank test, top left). Absence of TP53 mutations and presence of LOH 10q are predictive of shorter survival. EGFR amplification, p16INK4a homozygous deletion, and
PTEN mutations are not associated with prognosis of glioblastoma patients.
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(Fig. 6). The others included splicing mutations (11.5%), in-frame
deletions (7.7%), and point mutations in 5-untranslated region
(2.6%).
DISCUSSION
This is the first population-based study on glioblastomas that in-
cludes incidence, survival rates, and key genetic alterations. It has a
high degree of accuracy because the registry data were histologically
verified in 80% of cases. Furthermore, we reviewed the histopatho-
logic diagnosis in 96% of these cases according to new WHO Clas-
sification of Tumors of the Nervous System (2). The incidence rate of
glioblastomas in the Canton of Zurich, adjusted to the World Standard
Population per 100,000 population per year, was 3.32 in male cases
and 2.24 for female cases, and if adjusted to the United States
population, the rate was 4.63 in male cases and 2.88 in female cases.
The incidence rate in male cases in Zurich was higher than the value
of 3.69 recorded by the Central Brain Tumor Registry of the United
States (ref. 13; 1992 through 1997, adjusted to the United States
standard population), but the incidence rates in female cases were
similar in Zurich and the United States.
Despite progress in surgery and radiotherapy and chemotherapy of
brain tumors, the overall survival of patients with glioblastoma re-
mains extremely poor. In the present population-based study, only
17.7% survived 1 year, 3.3% lived 2 years, and only 1.2% of
patients were still alive 3 years after diagnosis. Similarly, a popula-
tion-based study in Canada showed that after exclusion of neoplasms
with a significant oligodendroglial component, only 15 of 689 glio-
blastoma patients (2.2%) diagnosed during 1975 to 1991 survived for
3 years (15). Clinical trials of patients with malignant glioma show a
better outcome because they usually combine glioblastomas and ana-
plastic astrocytomas. A recent meta-analysis showed that 40% of
patients with malignant glioma treated with radiotherapy and 46%
treated with radiotherapy plus chemotherapy survived 1 year (1).
However, clinical trials have a strong bias toward the recruitment of
patients with higher preoperative Karnofsky performance score and of
younger age (1). In this population-based study, 30% of patients were
70 years (see Materials and Methods). They typically have a low
Karnofsky performance score and would not be eligible for a therapy
trial, and they are less likely to be treated using surgery and radio-
therapy (see Materials and Methods). This is the main reason for the
low survival rates in the present population-based study when com-
pared with results of clinical trials and underlines that even in a
country with unrestricted access to a sophisticated health care system,
the prognosis of older patients with glioblastoma is still depressingly
poor.
Several therapy trials and hospital-based studies have shown that
younger glioblastoma patients (50 years) have a better prognosis
than older patients (7, 16–18). The present study clearly showed that
at the population level, age also was the most significant prognostic
factor in univariate and multivariate analyses. Furthermore, this effect
persisted through all of the age groups in a linear fashion, which
allows calculation of the mean and median survival time from the date
of glioblastoma diagnosis (Fig. 1).
Glioblastomas can be subdivided into primary and secondary neo-
plasms, which affect patients at different ages and through different
genetic pathways (2, 3). We show here that at the population-based
level, secondary glioblastomas are a rare disease, amounting to only
5% of all of the glioblastomas. This is consistent with the finding of
Dropcho et al. (19), who observed that 19 of 392 (5%) patients with
glioblastomas at the University of Alabama had histologically proven
previous low-grade gliomas. However, in the population-based series
of the California Cancer Registry, the number of newly diagnosed
cases of low-grade and anaplastic astrocytomas was6% and 24% of
incident glioblastoma cases (20). Similarly, in the present population-
based study, the incidence rate of low-grade and anaplastic gliomas is
approximately two or three times higher than that of secondary glio-
blastoma (21). The higher frequency of precursor lesions may be
explained at least in part by the fact that a fraction of patients with
low-grade or anaplastic astrocytoma die before progression to glio-
blastoma occurs. However, some cases with rapid progression from
low-grade or anaplastic astrocytoma may have been misclassified as
primary glioblastoma. Even considering this possibility, on a population-
based level, secondary glioblastomas constitute a rare disease when
compared with primary glioblastoma.
Univariate analysis revealed that patients with secondary glioblas-
toma survived significantly longer than those with primary glioblas-
toma, but this is likely because of the younger age of patients with
secondary glioblastomas rather than a reflection of different biological
behavior because the difference became nonsignificant in an age-
adjusted multivariate analysis. We observed that secondary glioblas-
tomas develop more frequently in women (male to female ratio, 0.65)
than primary glioblastomas (1.33). This corroborates a previous find-
ing that glioblastomas with TP53 mutations (a genetic hallmark of
Fig. 5. A, copresence of genetic alterations in glioblastomas. Percentages indicate
fraction of cases showing two different genetic alterations simultaneously. Note that LOH
10q plus other genetic alterations (TP53 mutations, EGFR amplification, p16INK4a ho-
mozygous deletion, and PTEN mutations) are frequent. To assess association between
genetic alterations, univariate analysis (A) and multivariate analysis (B) were carried out.
Both analyses revealed an association between EGFR amplification and p16INK4a deletion
and an inverse correlation between p16INK4a deletion and TP53 mutations (A and B). In
univariate analysis, inverse associations also were observed between EGFR amplification
and TP53 mutations, and EGFR amplification and PTEN mutations (A), and in multiva-
riate analysis, a positive association was observed between LOH 10q and TP53 mutations,
and an inverse association between PTEN mutations and EGFR amplification (B). Pos-
itive association. Inverse association. Age-adjusted hazard ratio. 95% CI.
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secondary glioblastomas) were more common in women (22). This is
surprising because in hospital-based studies (2, 23) and in this popu-
lation-based study, the incidence of low-grade or anaplastic gliomas in
male patients was similar to or higher than in female patients (21). The
possibility exists that gliomas progress more frequently or more
rapidly to glioblastoma in female patients.
The present study is one of the largest genetic analyses in glioblas-
tomas and the first carried out on a population. Although not all of the
archival samples (in particular, autopsy cases) were suitable for PCR
amplification, we were able to assess key genetic alterations in up to
71% of histologically diagnosed cases. The TP53 gene encodes a
protein that plays important roles in several cellular processes, includ-
ing the cell cycle, response to DNA damage, apoptosis, cell differen-
tiation, and neovascularization (24). Data on the predictive value of
TP53 mutations in glioblastomas are contradictory. Although some
hospital-based studies showed no association between TP53 status
and outcome of glioblastoma patients (17, 18), Schmidt et al. (25)
analyzed 97 glioblastoma cases and found that the presence of TP53
mutations was a favorable prognostic factor. In the present popula-
tion-based study, univariate analysis revealed that the presence of
TP53 mutations was predictive of longer survival (Fig. 4). However,
age-adjusted multivariate analysis revealed no difference in survival
between patients with and without TP53 mutations. It has been re-
ported that low-grade astrocytomas with a TP53 mutation at codon
175 showed a significantly worse prognosis than morphologically
similar tumors with mutations at other sites (26). In the present study,
there was a tendency that patients with glioblastoma carrying a TP53
codon 175 mutation had shorter survival times than those carrying
other mutations, but the difference was not statistically significant.
It is of interest to note that the type and distribution of TP53
mutations differed between glioblastoma subtypes. In secondary glio-
blastomas, 57% of mutations were located in the two hotspot codons,
248 and 273 (Fig. 6). In primary glioblastomas, mutations were more
equally distributed through exons, only 17% occurring in codons 248
and 273 (Fig. 6). Furthermore, G:C3A:T transitions at CpG sites
were significantly more frequent in secondary than in primary glio-
blastomas. The best-characterized mechanism of G:C3A:T transi-
tions at CpG sites is deamination of 5-methylcytosine, which is
clustered at CpG sites, resulting in substitution of 5-methylcytosine by
thymine. This occurs spontaneously or is factor mediated (e.g.,
through the action of oxygen radicals or by nitric oxide produced by
nitric oxide synthase in conditions of chronic inflammation; ref. 27).
Alternatively, our previous observation of a significant correlation
between TP53 mutations and promoter methylation of the O6-meth-
ylguanine-DNA methyltransferase (MGMT) gene in low-grade astro-
cytomas and secondary glioblastomas suggests the possible involve-
ment of endogenous or exogenous DNA alkylation at the O6-position
of guanine (28). In any case, G:C3A:T mutations at CpG sites,
particularly in hotspot codons 248 and 273, seem to be an early event
directly associated with malignant transformation in the pathway to
secondary glioblastomas, whereas the less specific pattern of TP53
mutations in primary glioblastomas may, in a majority of cases,
constitute secondary events reflecting increased genomic instability
during tumor progression.
Epidermal growth factor receptor (EGFR) is a transmembrane
receptor that binds to extracellular ligands such as epidermal growth
factor and transforming growth factor  and transduces a mitotic
signal (29). EGFR amplification has been identified as a genetic
hallmark of glioblastomas (2). The predictive value of EGFR ampli-
fication has been unclear. In previous studies (40 cases), EGFR
amplification was associated with poorer survival of glioblastoma
patients (30, 31). One study of 97 patients showed a lack of predictive
Fig. 6. A, distribution of TP53 point mutations in primary and
secondary glioblastomas. The majority (57%) of TP53 mutations in
secondary glioblastomas were located in codons 248 and 273,
whereas TP53 mutations in primary glioblastomas were more
equally distributed across different codons with a slight peak at
codons 248 and 273 (17%). B, distribution and type of PTEN
mutations in glioblastomas. Note that mutations leading to protein
truncation (nonsense mutation, deletion, insertion) are located
throughout the exons, whereas missense mutations are preferentially
located in exons 1 to 6 (i.e., in the region homologous to tensin,
auxilin, and dual-specificity phosphatases).
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value of EGFR amplification (25); similarly, a meta-analysis of seven
previous studies (total, 395 glioblastoma cases) did not detect a
significant predictive value of EGFR amplification (32). Shinojima et
al. (33) reported that EGFR amplification was a significant unfavor-
able predictor for overall survival in glioblastoma patients and that the
EGFR gene status was a more significant prognostic factor in younger
patients (60 years). Other studies reported that EGFR amplification
was a predictor of longer survival only in older glioblastoma patients
(18, 34). Simmons et al. (17) reported that EGFR overexpression was
associated with poorer survival of glioblastoma patients younger than
the median age and that EGFR overexpression was negatively asso-
ciated with survival in cases without the TP53 mutation. The present
population-based study indicates that the presence of EGFR amplifi-
cation does not affect survival of glioblastoma patients at any age. The
striking finding of EGFR amplification in the present study is the
unusual age distribution. EGFR amplification closely reflects the age
distribution of primary glioblastomas and was not detected in any
glioblastomas of patients 35 years (Fig. 2B).
The p16INK4a gene binds to cyclin-dependent kinase 4 and inhibits
the cyclin-dependent kinase 4–cyclin D1 complex (35, 36). This
complex phosphorylates the RB1 protein, thereby inducing release of
the E2F transcription factor that activates genes involved in the late
G1 and S phases (35, 36). In glioblastomas, disruption of the p16INK4a
gene occurs through homozygous deletion (2). Findings regarding the
predictive value of p16INK4a homozygous deletion have been incon-
sistent. In an analysis of 46 cases, Kamiryo et al. (37) reported that
homozygous p16INK4a deletion was a significantly unfavorable crite-
rion for survival of glioblastoma patients. Another study showed that
homozygous p16INK4a deletion was associated with shorter survival
only in a subgroup of glioblastoma patients 50 years of age (38). In
the present population-based study, univariate and multivariate anal-
yses failed to show any predictive value of homozygous p16INK4a
deletion. We did observe a significant association between EGFR
amplification and p16INK4a deletion, in agreement with the findings of
previous hospital-based studies based on a small numbers of cases
(39, 40).
PTEN gene locates on chromosome 10q23 and encodes a protein
that plays important roles in the regulation of cell proliferation,
apoptosis, and tumor invasion (41, 42). PTEN mutations have been
reported in 15 to 40% of glioblastomas (42, 43). PTEN homozygous
deletions may occur, but they are rare in glioblastomas (2%; ref.
44). Promoter methylation may be alternative mechanisms of loss of
PTEN expression, but the significance of PTEN methylation in the
evolution of glioblastomas remains to be clarified (45). In several
previous studies, PTEN mutations were not associated with prognosis
of glioblastoma patients (18, 25, 46), and this was confirmed in the
present population-based study. Interestingly, most missense muta-
tions were located in exons 1 to 6, the region homologous to tensin,
auxilin, and dual-specificity phosphatases, whereas nonsense muta-
tions and deletions/insertions leading to stop codons and protein
truncation were located more equally throughout the gene. This sug-
gests that cells with PTEN truncation at any site or PTEN missense
mutations in the region homologous to tensin/auxilin and dual-spec-
ificity phosphatases acquire transformed phenotype.
LOH 10 is the most frequent genetic alteration in glioblastomas
and occurs in 60 to 80% of cases (47–50). Many glioblastomas
seem to have lost one entire copy of chromosome 10. LOH occurs
most frequently at three common loci (i.e., 10p14-p15, 10q23–24,
and 10q25-pter), suggesting the presence of several tumor suppres-
sor genes (47– 49, 51). We show here that LOH 10q is the most
frequent genetic alteration in the pathways to primary and second-
ary glioblastomas. LOH 10q has been found to be associated with
reduced survival of glioblastoma patients in previous studies (25,
52, 53), and this was confirmed at the population level. The
presence of LOH 10q was the only genetic alteration associated
with shorter survival.
Several previous studies focused on genetic alterations and their
impact on survival of glioblastoma patients. However, most of
these were based on small case numbers and usually on a single
cancer-related gene. To obtain better understanding of effect of
copresence of different genetic alterations, we carried out analyses
of several key genetic alterations in a large number of glioblasto-
mas. Our population-based study shows that LOH 10q was typi-
cally copresented with any of the other genetic alterations (Fig. 5).
In contrast, TP53 mutations, p16INK4a deletion, EGFR amplifica-
tion, and PTEN mutations showed inverse associations with each
other, except for a positive correlation between p16INK4a deletion
and EGFR amplification (Fig. 5). This suggests that LOH 10q plus
at least one other genetic alteration may be operative in the
development of a majority of glioblastomas. LOH 10q25-qter
distal to the PTEN seems to be associated with acquisition of the
glioblastoma phenotype (54), suggesting that a tumor suppressor
gene in this region may be crucial in the development of glioblas-
tomas. Candidate genes include DMBT1 (52, 55) and FGFR2 (52).
Identification and validation of such a gene would be an important
advancement in our understanding of the pathogenesis of glioblas-
tomas and in devising new strategies for the management of this
most malignant brain tumor.
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